From: Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
Toxicity
1
2
3
4
No.
%
WBC/granulocytes
3.8
0
Platelets
1.9
Hemoglobin
7
13.5
27
51.9